@article{1a294789a2ec4ed69538284e7153ba97,
title = "Sustained virologic response after 6 weeks of therapy with a first-generation hepatitis C virus protease inhibitor",
author = "Andreas Kyvernitakis and Elias Jabbour and Torres, \{Harrys A.\}",
note = "Funding Information: Potential conflicts of interest. H. A. T. is a consultant for Gilead Sciences, Merck \& Co, No-vartis, Astellas, Pfizer, Theravance, Genentech, and Vertex Pharmaceuticals and has received research grants from Merck \& Co and Vertex Pharmaceuticals. All other authors report no potential conflicts.",
year = "2014",
month = may,
day = "1",
doi = "10.1093/cid/ciu070",
language = "English (US)",
volume = "58",
pages = "1342--1344",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "9",
}